No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 28 of the 40 quarters in the window, leaving 12 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:14.518Z. Latest historical point 2025-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:02:14.518Z. Latest historical point 2025-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:02:14.518Z. Latest historical point 2025-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:02:14.518Z. Latest historical point 2025-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:02:14.518Z. Latest historical point 2025-05-09.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:02:14.518Z. Latest historical point 2025-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:02:14.518Z. Latest historical point 2025-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:02:14.518Z. Latest historical point 2025-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Kiora Pharmaceuticals, Inc. (KPRX) stock was $2.52 as of Oct 6, 2026, 9:56 AM EDT, down 0.40% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -8.0% · 3-year avg -22.7%/yr · 5-year avg -67.1%/yr
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials.
Biotechnology · Encinitas, CA
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
-0.38
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.34
vs Estimate
$-0.47
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1KPRX | $11.17M | $2.52 | -0.40% | -7.96% | -67.06% | -55.97% | N/A |
| 2BFRI | $11.14M | $0.87 | -2.33% | -16.67% | N/A | N/A | vs KPRX |
| 3BIVI | $11.09M | $1.47 | +2.08% | -26.05% | -70.37% | -54.09% | vs KPRX |
| 4BFRG | $10.90M | $0.59 | -1.01% | -58.58% | N/A | N/A | vs KPRX |
| 5LSTA | $11.47M | $1.26 | +0.00% | -49.83% | -40.75% | -32.84% | vs KPRX |
| 6GDTC | $10.83M | $0.92 | -9.41% | -49.59% | N/A | N/A | vs KPRX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$12.00
+376.2% upside
Low
$12.00
Current
$2.52
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Quarter ending Dec 2026 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Quarter ending Mar 2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Quarter ending Jun 2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.67 | $-1.67 | $-1.67 | 1 |
| FY 2027 | $-0.85 | $-0.85 | $-0.85 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.50M | $1.50M | $1.50M | 1 |
| FY 2027 | $28.78M | $28.78M | $28.78M | 1 |
